Difference between revisions of "Radium-223 (Xofigo)"
(Created page with "'''In clinical trials.''' Also known as radium-223 chloride. ==General information== Class/mechanism: Radioactive pharmaceutical agent (radium-223) that mimics some biologic be...") |
m (PeterYang moved page Radium-223 (Alpharadin) to Radium Ra 223 (Xofigo): FDA approval) |
(No difference)
| |
Revision as of 15:52, 16 May 2013
In clinical trials. Also known as radium-223 chloride.
General information
Class/mechanism: Radioactive pharmaceutical agent (radium-223) that mimics some biologic behaviors of calcium and is incorporated into bone, where it can release alpha radiation at the site of bone metastases. The limited penetration of alpha radiation is believed to limit the risk of adverse side effects. Radium-223's half-life is 11.4 days.[1]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Clinical trials
- Nilsson S, Strang P, Aksnes AK, Franzèn L, Olivier P, Pecking A, Staffurth J, Vasanthan S, Andersson C, Bruland OS. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012 Mar;48(5):678-86. Epub 2012 Feb 15. PubMed
- Overall Survival Benefit of Radium-223 Chloride (Alpharadin) in the Treatment of Patients With Symptomatic Bone Metastases in Castration-Resistant Prostate Cancer (CRPC): A Phase III Randomised Trial (ALSYMPCA)
- Study of Radium-223 for the Palliation of Painful Bone Metastases in Hormone Refractory Prostate Cancer (HRPC) Patients
- A Study of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
- Radium-223 Chloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
- A Study of Alpharadin® in Breast Cancer Patients With Bone Dominant Disease no Longer Considered Suitable for Hormone Therapy
Patient drug information
No information available.